CA3207494A1 - Hhla2 binding agents with novel activity - Google Patents
Hhla2 binding agents with novel activityInfo
- Publication number
- CA3207494A1 CA3207494A1 CA3207494A CA3207494A CA3207494A1 CA 3207494 A1 CA3207494 A1 CA 3207494A1 CA 3207494 A CA3207494 A CA 3207494A CA 3207494 A CA3207494 A CA 3207494A CA 3207494 A1 CA3207494 A1 CA 3207494A1
- Authority
- CA
- Canada
- Prior art keywords
- hhla2
- antibody
- seq
- binding
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142832P | 2021-01-28 | 2021-01-28 | |
| US63/142,832 | 2021-01-28 | ||
| PCT/US2022/014423 WO2022165258A1 (en) | 2021-01-28 | 2022-01-28 | Hhla2 binding agents with novel activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3207494A1 true CA3207494A1 (en) | 2022-08-04 |
Family
ID=82652818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3207494A Pending CA3207494A1 (en) | 2021-01-28 | 2022-01-28 | Hhla2 binding agents with novel activity |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250270323A1 (enExample) |
| EP (1) | EP4284431A4 (enExample) |
| JP (2) | JP2024509501A (enExample) |
| KR (1) | KR20230135637A (enExample) |
| CN (1) | CN116981476A (enExample) |
| AU (1) | AU2022214939A1 (enExample) |
| BR (1) | BR112023014826A2 (enExample) |
| CA (1) | CA3207494A1 (enExample) |
| IL (1) | IL304584A (enExample) |
| MX (1) | MX2023008182A (enExample) |
| WO (1) | WO2022165258A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122161832A (zh) * | 2023-09-08 | 2026-06-05 | Nextpoint治疗公司 | 抗体-药物缀合物 |
| CN119841949B (zh) * | 2023-10-17 | 2026-06-05 | 科辉智药(深圳)新药研究中心有限公司 | 一种抗人hhla2的纳米抗体及其应用 |
| CN121005781A (zh) * | 2024-05-24 | 2025-11-25 | 合肥天港免疫药物有限公司 | 高亲和力b7h7抗体或其抗原结合片段及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015167948A1 (en) * | 2014-04-30 | 2015-11-05 | Albert Einstein College Of Medicine Of Yeshiva University | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies |
| TWI917306B (zh) * | 2017-07-06 | 2026-03-11 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的結合分子 |
| MX2020010094A (es) * | 2018-04-06 | 2021-01-15 | Dana Farber Cancer Inst Inc | Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos. |
| CN111196852A (zh) * | 2018-11-16 | 2020-05-26 | 四川科伦博泰生物医药股份有限公司 | 抗tigit抗体及其用途 |
-
2022
- 2022-01-28 WO PCT/US2022/014423 patent/WO2022165258A1/en not_active Ceased
- 2022-01-28 BR BR112023014826A patent/BR112023014826A2/pt unknown
- 2022-01-28 MX MX2023008182A patent/MX2023008182A/es unknown
- 2022-01-28 CA CA3207494A patent/CA3207494A1/en active Pending
- 2022-01-28 EP EP22746752.9A patent/EP4284431A4/en active Pending
- 2022-01-28 JP JP2023544261A patent/JP2024509501A/ja active Pending
- 2022-01-28 US US18/263,313 patent/US20250270323A1/en active Pending
- 2022-01-28 KR KR1020237028708A patent/KR20230135637A/ko active Pending
- 2022-01-28 AU AU2022214939A patent/AU2022214939A1/en active Pending
- 2022-01-28 CN CN202280012137.1A patent/CN116981476A/zh active Pending
-
2023
- 2023-07-19 IL IL304584A patent/IL304584A/en unknown
-
2026
- 2026-05-07 JP JP2026078333A patent/JP2026119212A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230135637A (ko) | 2023-09-25 |
| JP2024509501A (ja) | 2024-03-04 |
| WO2022165258A1 (en) | 2022-08-04 |
| BR112023014826A2 (pt) | 2023-10-03 |
| EP4284431A4 (en) | 2025-01-15 |
| IL304584A (en) | 2023-09-01 |
| EP4284431A1 (en) | 2023-12-06 |
| JP2026119212A (ja) | 2026-07-16 |
| US20250270323A1 (en) | 2025-08-28 |
| CN116981476A (zh) | 2023-10-31 |
| AU2022214939A1 (en) | 2023-07-20 |
| MX2023008182A (es) | 2023-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110352200B (zh) | 抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用 | |
| US20200291114A1 (en) | Anti-cd47 antibodies and methods of use | |
| CN107921122B (zh) | 与cd38结合的抗体治疗剂 | |
| TWI564306B (zh) | 雙特異性抗體 | |
| CN114269389B (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| JP2023541473A (ja) | 抗４－１ｂｂ－抗ｐｄ－ｌ１二重特異性抗体、ならびにその医薬組成物および使用 | |
| CN110545845A (zh) | 抗cd33抗体药剂 | |
| JP7851303B2 (ja) | ヒトｃｄ３イプシロンに結合する新規なヒト抗体 | |
| US20250270323A1 (en) | Hhla2 binding agents with novel activity | |
| JP2023524102A (ja) | Ａｂｃｂ５に特異的な抗体およびその使用 | |
| US20210277139A1 (en) | Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof | |
| JP2023541853A (ja) | Ｐｄ－１ポリペプチド変異体 | |
| JP2025511002A (ja) | 活性化可能な二重特異性抗ｃｄ３および抗ｐｄ－ｌ１タンパク質ならびにその使用 | |
| US20250138018A1 (en) | T cell and nk cell engagers | |
| WO2020204033A1 (ja) | がん治療用医薬 | |
| HK40102688A (en) | Hhla2 binding agents with novel activity | |
| WO2025175056A1 (en) | Multispecific antibodies or antigen binding fragments thereof to b7-h7 and immune effector cell antigens | |
| TW202523694A (zh) | 抗muc16抗體及其用途 | |
| HK40060959A (en) | Antibody therapeutics that bind cd38 | |
| HK1253584B (en) | Antibody therapeutics that bind cd38 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250124 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250124 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260123 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260123 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260209 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260217 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260217 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260227 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260227 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260302 |